Encore PFO Closure Device - The PerFOrm Trial

Официальное название

Encore PFO Closure Device U.S. IDE Randomized Trial - The PerFOrm Trial

Обзор

The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when compared to any investigator chosen FDA-approved PFO closure device.

Подробное описание

This is a prospective, multicenter, randomized clinical study to determine the safety and effectiveness of the Encore PFO closure device, which is indicated for percutaneous, transcatheter closure of a patent foramen ovale (PFO) in patients who have had a cryptogenic stroke due to a presumed paradoxical embolism.

Вмешательства

• Устройство Encore PFO closure device
  The Encore PFO closure device comprises an implant component and a single-use delivery system.
• Устройство FDA-approved PFO closure device
  Chosen by the investigator

Первичные конечные точки

• Safety: The incidence of device- or procedure-related serious adverse events (SAEs) [Срок оценки: 6 months]
• Effectiveness: Effective closure [Срок оценки: 6 months]

Вторичные конечные точки (6)

• Complete closure [Срок оценки: 6 months]
• Occurrence of recurrent symptomatic cryptogenic non-fatal stroke or cardiovascular death [Срок оценки: 5 years]
• Occurrence of transient ischemic attacks (TIA) [Срок оценки: 5 years]
• Occurrence of clinically significant new atrial arrhythmia (including atrial fibrillation) [Срок оценки: 5 years]
• Occurrence of technical success [Срок оценки: Procedural]
• Occurrence of procedural success [Срок оценки: Procedural]

Критерии участия

Критерии включения

• Diagnosis of PFO, defined as visualization of microbubbles per TEE in the left atrium within three cardiac cycles from the right atrial opacification demonstrating right-to-left shunting at rest and/or during Valsalva release
• Cryptogenic stroke within the last 270 days; stroke is defined as acute focal neurological deficit, presumed to be due to focal ischemia, and confirmed by MRI or CT to be a new, neuroanatomically relevant cerebral infarct

Критерии исключения

• Age <18 years and age >60 years
• Greater than 50% lumen diameter stenosis of intracranial or extracranial vessels
• Intracardiac thrombus or tumor
• Acute or recent (within 6 months) myocardial infarction (MI) or unstable angina
• Left ventricular aneurysm or akinesis
• Mitral valve stenosis (mitral valve area less than 1.5cm2) or severe mitral regurgitation
• Aortic valve stenosis (gradient >40 mmHg) or severe aortic valve regurgitation
• Mitral or aortic valve vegetation or prosthesis
• Left ventricular ejection fraction <35%
• Other identifiable cause of stroke, including but not limited to aortic arch plaques (protruding >4 mm into the lumen), large artery atherosclerotic disease, an established cardioembolic source, small-vessel occlusive disease, or arterial dissection
• Evidence of a hypercoagulable disorder requiring anticoagulation therapy; this determination will be based on the evaluation of: anticardiolipin antibody (Ab) of the IgG or IgM type, Lupus anticoagulant, B2-glycoprotein-1 Ab, and fasting plasma homocysteine
• Another source of right-to-left shunts identified at baseline, including an atrial septal defect and/or fenestrated septum
• Any history of atrial fibrillation/atrial flutter (chronic or intermittent)
• Active endocarditis or other untreated infections
• Chronic kidney disease stage 4 or higher or end-stage renal failure requiring dialysis (eGFR less than 30)
• Severe liver disease (ALT 3X ULN) or documented cirrhosis
• Lung disease requiring continuous home oxygen
• Uncontrolled hypertension, defined as sustained elevated blood pressure >160/90 mm Hg on medication
• Uncontrolled diabetes mellitus, defined as HbA1c greater than 9 (based on most recent test which must have been collected within the last year)
• Anatomical or physiological structures that do not permit TEE
• Anticipated need for treatment of structural cardiac defects other than PFO
• Concomitant cardiac anomalies requiring an operative procedure
• Hemorrhagic diseases (e.g., coagulopathy, tendency to hemolysis)
• Hypersensitivity to contrast medium or nickel
• Contraindication to aspirin or clopidogrel
• The required sheaths cannot be passed through the relevant vessels for access to the PFO
• Vulnerable patient (e.g., incarcerated or cognitively challenged adults); see Section 7.2.1
• Subject is unable or unwilling to provide informed consent
• Subject is unable to comply with the protocol
• Any other clinical reasons for which the patient would not be an appropriate candidate for the study, as determined by the site investigators

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 8 центров

• Arkansas Cardiology — Little Rock
• Southern CA Permanente Medical Group - Kaiser San Diego and Scripps Memorial Hospital — La Jolla
• University of South Florida — Tampa
• Mercy One Iowa Heart Center — West Des Moines
• Kansas University Medical Center — Kansas City
• Jackson Heart Clinic — Jackson
• CHI Health — Omaha
• Medical University of South Carolina Gazes Research Institute — Charleston

Идентификаторы

NCT: NCT05537753 · ENC-CL-5000

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗